SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-068730
Filing Date
2024-06-04
Accepted
2024-06-04 16:30:33
Documents
11
Period of Report
2024-05-31
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20240531.htm   iXBRL 8-K 42258
  Complete submission text file 0000950170-24-068730.txt   152800

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20240531.xsd EX-101.SCH 23930
14 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20240531_htm.xml XML 4536
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 241018614
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)